What is holding back gene therapy for rare diseases?
Odylia CSO Harrison Brown, PhD spoke at the 2019 meeting of the American Society of Gene and Cell Therapy on the issues ...
About Odylia
Our Path
Resources
Consortium
What we do
Odylia Therapeutics is a non-profit corporation working to bring treatments for rare eye disease from the lab into humans using genetic therapies. Today, there are more than 300 known genetic forms of Inherited Retinal Disease (IRD) that lead to blindness, with some of these interfering with other sensory mechanisms like hearing and balance. Most are extremely rare, impacting less than one in a million people worldwide.
Why we exist
Although pre-clinical proof-of-concept treatments exist for some of these diseases, because they are so rare, there is little commercial interest in them. Odylia was formed to find a way to move these potential therapies into clinical trials to protect and restore the vision of those going blind.
Why we exist
Although pre-clinical proof-of-concept treatments exist for some of these diseases, because they are so rare, there is little commercial interest in them. Odylia was formed to find a way to move these potential therapies into clinical trials to protect and restore the vision of those going blind.
Latest news
Stay up-to-date with our research and clinical trials
-
-
Odylia Presents Gene Therapy Commercialization Workshop
March 26, 2019 (Boston, MA) Odylia Therapeutics Chief Scientific Officer Harrison Brown led a workshop on the challenges...
-
Odylia holds inaugural Gene Therapy Pre‑Competitive Consortium
March 25, 2019 (Boston, MA) The inaugural meeting of the Odylia Gene Therapy Pre-Competitive Consortium has been held at...